bs-13067R [Primary Antibody]
ELK4 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: ELK4

Immunogen Range: 21-120/431


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 2005

Source: KLH conjugated synthetic peptide derived from human ELK4/SAP-1a

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.

Background:

Serum response factor (SRF) is a transcription factor that binds the serum response element (SRE), a sequence that mediates the transient response of many cellular genes to growth stimulation. SRF-binding sites are also constitutive promoter elements in many muscle-specific promoters. At the c-Fos SRE, formation of a ternary complex containing SRF and its accessory protein p62TCF appears to be important for signal transduction. Two related Ets domain proteins, Elk-1 and SRF accessory protein-1 (SAP-1), have DNA binding properties identical to that of p62TCF. Elk-1 and SAP-1 contain two homologous regions of which the two amino terminal regions, the Ets domain (box A) and the B box, mediate ternary complex formation with SRF. The third homologous region, the C box located toward the C-terminus of the proteins, contains conserved consensus phosphorylation sites for MAP kinases.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 47


Cross Reactive Species: Mouse
Rat

Predicted Cross Reactive Species: Human
Dog
Cow
Sheep
Pig
Horse

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: Mouse Liver tissue lysates; Lane 2: Mouse Cerebellum tissue lysates; Lane 3: Rat Liver tissue lysates probed with ELK4 Polyclonal Antibody, Unconjugated (bs-13067R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.